Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Chinese Patients with Advanced Solid Tumors
NCT02825940Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2016
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of atezolizumab in gastric cancer (GC), nasopharyngeal carcinoma (NPC), esophageal cancer and 2 more (2 arms), sponsored by Roche. Primary endpoints: Maximum Observed Plasma Concentration up to 3 years, Minimum Observed Plasma Concentration up to 3 years and 6 more. Started Aug 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
gastric cancer (GC)nasopharyngeal carcinoma (NPC)esophageal cancerhepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02825940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02825940.